Synaptogenix Announces Live Appearance of its President and CSO on Streaming Financial News Network
Synaptogenix, Inc. (SNPX) announced that Dr. Daniel Alkon, President and CSO, will appear on TD Ameritrade Network's "The Watch List" on June 25, 2021, at 1:20 PM ET. He will discuss Synaptogenix's lead drug Bryostatin-1, focusing on its regenerative mechanism for treating Alzheimer's disease and its implications for future therapies following Biogen's recent drug approval. Synaptogenix is developing therapies for neurodegenerative diseases and has received Orphan Drug Designation for Bryostatin-1 aimed at Fragile X syndrome, highlighting the drug's clinical significance.
- Dr. Daniel Alkon's appearance on a financial news network enhances visibility and awareness of Synaptogenix and its lead drug, Bryostatin-1.
- Bryostatin-1 has received Orphan Drug Designation for treating Fragile X syndrome, indicating regulatory support and potential market advantage.
- The company has a significant safety database for Bryostatin-1, having tested it in over 1,500 individuals.
- No specific financial data or revenue metrics were provided in the PR, which may leave investors uncertain about the company's financial health.
- Forward-looking statements include risks such as the potential failure to achieve regulatory approval or the successful commercialization of Bryostatin-1.
NEW YORK, June 24, 2021 /PRNewswire/ -- Synaptogenix, Inc. (Nasdaq: SNPX), an emerging biopharmaceutical company focused on developing therapies for neurodegenerative diseases, today announced that Dr. Daniel Alkon, the Company's President and Chief Scientific Officer, will appear as a featured guest on TD Ameritrade Network's "The Watch List" on Friday, June 25, 2021 at 1:20pm ET (www.TDameritradenetwork.com).
Dr. Alkon will discuss the progression of treatments for Alzheimer's disease ("AD"), the regenerative mechanism of action for Synaptogenix's lead drug, Bryostatin-1, and how the recently approved drug from Biogen may impact future treatments in the AD space.
The Watch List, hosted by Nicole Petallides, highlights a panel of experts ranging from industry-leading Executives, analysts, and Wall Street influencers to discuss pressing topics moving the market and is intended to provide viewers with a status update for the end of the trading day and beyond.
About Synaptogenix, Inc.
Synaptogenix is a clinical-stage biopharmaceutical company that has historically worked to develop novel therapies for neurodegenerative diseases. Synaptogenix has conducted clinical and preclinical studies of its lead therapeutic candidate, Bryostatin-1, in Alzheimer's disease. Preclinical studies have also demonstrated Bryostatin's regenerative mechanisms of action for the rare disease, Fragile X syndrome, and for other neurodegenerative disorders such as multiple sclerosis, stroke, and traumatic brain injury. The U.S. Food and Drug Administration has granted Orphan Drug Designation to Synaptogenix for Bryostatin-1 as a treatment for Fragile X syndrome. Bryostatin-1 has already undergone testing in more than 1,500 people in cancer studies, thus creating a large safety data base that will further inform clinical trial designs.
Additional information about Synaptogenix, Inc. may be found on its website: www.synaptogen.com.
Forward-Looking Statements
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. These forward-looking statements include statements regarding the Phase 2 clinical trial of Bryostatin-1 and further studies, and continued development of use of Bryostatin-1 for AD and other cognitive diseases. Such forward-looking statements are subject to risks and uncertainties and other influences, many of which the Company has no control over. There can be no assurance that the clinical program for Bryostatin-1 will be successful in demonstrating safety and/or efficacy, that we will not encounter problems or delays in clinical development, or that Bryostatin-1 will ever receive regulatory approval or be successfully commercialized. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. Additional factors that may influence or cause actual results to differ materially from expected or desired results may include, without limitation, the Company's inability to obtain adequate financing, the significant length of time associated with drug development and related insufficient cash flows and resulting illiquidity, the Company's patent portfolio, the Company's inability to expand its business, significant government regulation of pharmaceuticals and the healthcare industry, lack of product diversification, availability of the Company's raw materials, existing or increased competition, stock volatility and illiquidity, and the Company's failure to implement its business plans or strategies. These and other factors are identified and described in more detail in the Company's filings with the Securities and Exchange Commission. The Company does not undertake to update these forward-looking statements.
Contact information:
Investors and Media
Investor Relations
Brett Maas
Hayden IR
brett@haydenir.com
(646)536-7331
Robert Weinstein
Chief Financial Officer
Synaptogenix, Inc.
rweinstein@synaptogen.com
View original content:http://www.prnewswire.com/news-releases/synaptogenix-announces-live-appearance-of-its-president-and-cso-on-streaming-financial-news-network-301319374.html
SOURCE Synaptogenix, Inc.
FAQ
When will Dr. Daniel Alkon appear on TD Ameritrade Network?
What will Dr. Alkon discuss during his appearance?
What is Bryostatin-1 used for?
What is Synaptogenix's focus as a biopharmaceutical company?
